Penumbra, Inc. (NYSE:PEN) Director Sells $5,005,000.00 in Stock

Penumbra, Inc. (NYSE:PEN – Get Rating) Director Arani Bose sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $250.25, for a total transaction of $5,005,000.00. Following the completion of the sale, the director now directly owns 445,662 shares in the company, valued at $111,526,915.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Penumbra Stock Down 1.9 %

Penumbra stock traded down $4.74 during midday trading on Wednesday, reaching $238.86. The company’s stock had a trading volume of 319,405 shares, compared to its average volume of 334,301. The business has a 50-day simple moving average of $220.08 and a 200-day simple moving average of $186.90. The company has a market cap of $9.07 billion, a P/E ratio of -291.29 and a beta of 0.48. Penumbra, Inc. has a fifty-two week low of $114.86 and a fifty-two week high of $253.22. The company has a quick ratio of 2.92, a current ratio of 5.23 and a debt-to-equity ratio of 0.03.

Penumbra (NYSE:PEN – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $213.68 million for the quarter, compared to analyst estimates of $212.41 million. Penumbra had a positive return on equity of 0.45% and a negative net margin of 3.68%. On average, research analysts expect that Penumbra, Inc. will post 0.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Truist Financial boosted their target price on Penumbra from $228.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Canaccord Genuity Group cut their price objective on Penumbra from $203.00 to $185.00 and set a “buy” rating on the stock in a report on Friday, November 4th. Citigroup lifted their target price on Penumbra from $212.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, December 12th. BTIG Research boosted their price target on shares of Penumbra from $204.00 to $240.00 and gave the stock a “buy” rating in a research note on Monday, December 5th. Finally, Royal Bank of Canada raised their price objective on shares of Penumbra from $195.00 to $215.00 in a research note on Monday, November 14th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Penumbra currently has an average rating of “Moderate Buy” and an average price target of $238.55.

Institutional Trading of Penumbra

Institutional investors have recently modified their holdings of the stock. Raymond James & Associates grew its position in shares of Penumbra by 8.1% in the 1st quarter. Raymond James & Associates now owns 8,565 shares of the company’s stock valued at $1,903,000 after buying an additional 641 shares during the last quarter. Citigroup Inc. grew its holdings in shares of Penumbra by 44.5% during the first quarter. Citigroup Inc. now owns 4,979 shares of the company’s stock worth $1,106,000 after purchasing an additional 1,534 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Penumbra by 15.7% during the first quarter. PNC Financial Services Group Inc. now owns 1,211 shares of the company’s stock worth $269,000 after purchasing an additional 164 shares in the last quarter. Great West Life Assurance Co. Can lifted its holdings in shares of Penumbra by 8.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 19,045 shares of the company’s stock valued at $4,348,000 after purchasing an additional 1,417 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Penumbra by 3.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 90,610 shares of the company’s stock valued at $20,123,000 after purchasing an additional 2,717 shares during the period. Hedge funds and other institutional investors own 82.42% of the company’s stock.

About Penumbra

(Get Rating)

Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons.